challenges to drug development in academia
DESCRIPTION
Challenges to Drug Development in Academia. Charles L. Sawyers, M.D. Chair, Human Oncology and Pathogenesis Program (HOPP) Investigator, Howard Hughes Medical Institute Memorial Sloan-Kettering Cancer Center; New York, NY. Disclosure. - PowerPoint PPT PresentationTRANSCRIPT
Challenges to Drug Development in
Academia
Charles L. Sawyers, M.D.Chair, Human Oncology and
Pathogenesis Program (HOPP)
Investigator, Howard Hughes Medical Institute
Memorial Sloan-Kettering Cancer Center; New York,
NY
Disclosure
I am a co-inventor of the drug MDV3100, now in a phase III clinicaltrial in prostate cancer, and I own stock in the company Medivation.
Two translational tales
1) Dasatinib (Sprycel) in chronic myeloid leukemia:
serendipitous marriage of a discovery in academia that reshaped a pharma-driven drug development program
2) MDV3100 in prostate cancer:
academia-based target validation and drug screening project that resulted in a biotech/pharma licensing deal for clinical development
The Ph Chromosome: t(9;22) Translocation
22
bcr
abl
Ph ( or 22q-)
bcr-abl
FUSION PROTEINWITH TYROSINEKINASE ACTIVITY
9 9 q+
Normal CML
Imatinib/STI571 (Gleevec) blocks BCR-ABL
Goldman JM, Melo JV. NEJM. 344:1084-1086
Blood counts of the first 6 patients who took 300 mg/day of Gleevec
WBC
x 1
03
100
10
1
0 30 60 90 120150 Days on Gleevec
Gleevec is not a cure:
Small numbers of CML cells are detected in patients who are in “remission.”
Patients can relapse while taking Gleevec.
Why?
WILD-TYPE T315I MUTANT (MODEL)
A mutation isolated from patients who relapse on Gleevec blocks drug binding to BCR-ABL
(Gorre et al Science, 2001)
E255K/V
BCR-ABL Kinase Domain Mutations Associated with Imatinib Resistance
M244V M351T
L248V
Y253H/F
E279K
F317L
E355G/DF359C/V/D
H396R/PQ252H/R
S417Y
E459K
F486S
E450G
M388L G250E
D276GT277A
L387F/M
V379I
A397P
P-loop Activation loop
E453G/K
T315I/DF311L/I
V289AL298V
> 50 distinct mutations reported
Imatinib resistance mutations impairconformational flexibility of the ABL kinase
John Kuriyan, Bhushan Nagar (UC-Berkeley)
P loopDirect contact with drughinge
Location of Mutations
Problem: Over 50 different mutations can cause resistance to Gleevec
Structural biology prediction: Mutations change the shape of BCR-ABL so that it favors the “open” conformation.
Solution: Drugs that target the “open” conformation should work in patients with Gleevec resistance.
How do we deal with resistance?
Dasatinib Gleevec
The SRC/ABL inhibitor dasatinib (BMS-354825) is active against all but one of the known mutations in BCR-ABL that
confer imatinib resistance
0
0.2
0.4
0.6
0.8
1
1.2
0 1 5 10 50 100
BCR/ABL/WTM244VG250EQ252HQ252RY253FY253HE255KE255VT315IF317LM351TE355GF359VH396RF486SBa/F3
nM BMS-354825
Nor
mal
ized
cel
l via
bilit
y
Shah et al Science, 2004
T315I
F317L
wt BCR-ABL
BCR-ABL genotype predicts clinical response to dasatinib
Talpaz ….Sawyers, NEJM, 2006
1) Imatinib has been frontline CML therapy
-75% of patients achieve complete cytogenetic response -20% relapse within 5 years, usually with mutant BCR-ABL
2) Dasatinib and nilotinib were initially approved as 2nd line therapy for imatinib-resistant CML (2006, 2007)
3) Upfront comparisons show than 2nd generation compounds are superior to imatinib
(Kantarjian et al NEJM 2010; Saglio et al NEJM 2010)
Chronic Myeloid Leukemia: 2010
Inhibition of androgen receptor (AR) signaling
AR
Androgen receptor
P
AR kinases
testosteronehormone
CoR vs Coactivators
ARARPol II
ARE
NCoR/HDACCyto
plasm
nucleus
P P Transcription of AR target genes eg PSAActivation of TMPRSS/ERG fusion
LHRH agonists
Anti-androgens Bicalutamide* Flutamide*
*Both drugs are partial agonists/antagonists
Typical Response to Hormone Therapy
Time
Dis
ease
Bur
den Hormone Therapy
Discontinue Antiandrogen
1) AR is overexpressed in castration resistant sublines of multiple prostate cancer xenograft models (and in patients)
2) Forced AR overexpression confers castration-resistance3) AR knockdown impairs castration-resistant growth4) AR antagonists act as agonists when AR levels are high
(Chen et al Nature Med, 2004)
Primary Mechanism of Resistance to Castration and/or Current Antiandrogens
AR is required to maintaincastrate resistance in vivo
Tum
or v
olum
e (m
m3 )
0
200
400
600
0 24 48 72
Vector
AR shRNA
**
**
Time (days)
0
50
100
150
200
0 24 48 72
Vector
AR shRNA
*
**
**
LAPC4/CR LNCaP/CR
5’ LTR 3’ LTRGFPCMVTerm.AR RNAiU6
AR shRNA GFPLentivirus vector
Growth of castrate resistant xenografts in castrate male mice
1) AR is overexpressed in castration resistant sublines of multiple prostate cancer xenograft models (and in patients)
2) Forced AR overexpression confers castration-resistance3) AR knockdown impairs castration-resistant growth4) AR antagonists act as agonists when AR levels are high
(Chen et al Nature Med, 2004)
Primary Mechanism of Resistance to Castration and/or Current Antiandrogens
Second generation anti-androgens must:
• be effective in cells expressing high levels of androgen receptorAND
• overcome the problem of antagonist/agonist conversion
Design tools: - Crystal structure
- Homology modeling
- Binding affinity
NC
F3C N N
O
S
OH
RU 59063
High AR binding affinity(Ka = 20 nM for human AR)But with agonistic activity
Samedy Ouk, Michael Jung (UCLA Department of Chemistry)
Cell-based screen for compounds with greater antagonism and no agonism (“pure antagonists”)
Binding affinity to ARAntagonist Activity
NF3C
NC
N
O
S
R1
R2
R
H-bond interaction
Hydrophobicinteraction
Rigidity
Hydrophobicinteractions with AR Jung et al, J Med Chem, 2010
Bic RD162 MDV3100Veh
Bic RD162 MDV3100Veh
RD162 and MDV3100 do not display agonism in AR overexpressing cells
Bic RD162 MDV3100Veh
Bic RD162 MDV3100Veh
…and have more potent antagonist activity
PSA TMPRSS2
Tran et al, Science 2009
Immunodeficient SCID castrate male mice. Tumor volume was measured in 3 dimensions.
Tran et al, Science 2009
bicalutamide
RD162 (and MDV3100) are superior to bicalutamide in the castrate-resistant LNCaP-AR xenograft model
Androgen receptor activation and mechanism of antiandrogen action
Revised from Lancet Oncol. 2009 Oct;10(10):981-91.
Androgen (R1881) Bicalutamide
MDV3100
R188142284
R1881+Bicalutamide31832
R1881+MDV1793
R1881 (androgen)
MDV
Overlap among AR binding peaks in response to antagonists (determined by AR ChIP-Seq)
peaks found by MACS, p-value <10-5
42284
Bicalutamide18075
451
Ling Cai
A Phase 1-2 Multicenter First-in-Man Trial of MDV3100 in Castrate Resistant Prostate Cancer
1. Dose escalation, 3 patients per cohort, beginning at 30 mg/d to 600 mg/d
2. After safety was established at 60 mg/d, cohorts were expanded to 24 patients (12 chemo-naïve, 12 chemo failure)
3. First patient dosed in July, 20074. 140 men enrolled at 5 centers
(MSKCC, OHSU, U Wash, DFCI, MDACC)
Scher et al Lancet, 2010
Waterfall Plot of Best Percent PSA Change from Baseline
Chemotherapy-Naïve (N=65) Post-Chemotherapy (N=75)
62% (40/65)
>50% Decline
51% (38/75)
>50% Decline
Radiographic Changes in Soft Tissue (N=59) and in Bone (N=109)
Chemotherapy-Naïve Patients (N=65)
Post-Chemotherapy Patients (N=75)
Soft Tissue* (Best Response)
Partial Response
Stable Disease
N=25
36% (9/25)
44% (11/25)
N=34
12% (4/34)
53% (18/34)
Bone Scan (Week 12)
Stable Disease
N=41
63% (26/41)
N=68
51% (35/68)
*59 patients with evaluable soft tissue disease as defined by PCWG2 consensusJ Clin Oncol 2008.
Time to PSA Progression For Pre-and Post-Chemotherapy Treated Patients
Pre (Not reached)
Post (186 days)
Summary
1. Castration resistant prostate cancer remains dependent on androgen receptor (AR) function.
2. Pure AR antagonists like MDV3100 can overcome clinical resistance to partial antagonists (bicalutamide).
3. MDV3100 likely induces an AR conformation that precludes DNA binding.
4. MDV3100 development has progressed to a phase III registration trial in castration resistant, chemotherapy resistant prostate cancer
Mercedes Gorre Neil Shah John Nicoll
BMS clinical trialMoshe TalpazArt DecillisClaude NicaiseEric Bleickardt
Bhushan NagarJohn Kuriyan (UC Berkeley)Frank Lee (BMS)
Collaborators
Chris TranMike Burgess
Ron Paquette Liz Haddad
CML/Abl Inhibitor Project
Charlie Chen Derek Welsbie Chris TranJohn Wongvipat
Michael Jung(Chemistry)
Samedy Ouk(Chemistry)
Nicola Clegg
David Hung Medivation
Prostate Cancer/Antiandrogen Project